Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Lau

Showing results (51-60 of 54) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 54 results.
Molecular Cancer Therapeutics|May 18, 2018
Orally Bioavailable and Blood-Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in MiceJeremy Karlin, Jasmine Allen, Syed F Ahmad, et al.
Cancer Cell|July 11, 2025
KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancerAna Galan-Cobo, Natalie I Vokes, Yu Qian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2022
Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor ResistanceVioleta Serra, Anderson T Wang, Marta Castroviejo-Bermejo, et al.
Nature Communications|February 24, 2024
The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironmentElizabeth L Hardaker, Emilio Sanseviero, Ankur Karmokar, et al.
Pageof 6

Showing results (51-60 of 54) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 54 results.
Molecular Cancer Therapeutics|May 18, 2018
Orally Bioavailable and Blood-Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in MiceJeremy Karlin, Jasmine Allen, Syed F Ahmad, et al.
Cancer Cell|July 11, 2025
KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancerAna Galan-Cobo, Natalie I Vokes, Yu Qian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2022
Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor ResistanceVioleta Serra, Anderson T Wang, Marta Castroviejo-Bermejo, et al.
Nature Communications|February 24, 2024
The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironmentElizabeth L Hardaker, Emilio Sanseviero, Ankur Karmokar, et al.
Pageof 6